AVI BioPharma, Inc. And Ercole Biotech Announce Cross-License And Drug Discovery Collaboration For Alternative Splicing Therapeutics

Published: Dec 20, 2006

PORTLAND, Ore. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), and Ercole Biotech, Inc., announced today a cross-license and collaboration agreement to identify and develop drugs that direct the splicing of messenger RNA (mRNA) to treat a variety of genetic and acquired diseases. Under the terms of the agreement, each party is granting the other rights under their respective patents for RNA splice-altering technologies.

Back to news